News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mirna Therapeutics, Inc. Announces Scientific Publication That Suggests Enhanced Potency Of Lead Therapeutic Microrna In Combination With FDA Approved Lung Cancer Dru


2/18/2014 9:54:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc., a leading, privately held clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, announced today the publication of new preclinical data suggesting that microRNA-34 (miR-34) and erlotinib, an EFGR inhibitor approved to treat non-small cell lung cancer (NSCLC), cooperate synergistically to inhibit proliferation of certain erlotinib-resistant NSCLC cells and hepatocellular carcinoma (HCC) cells in vitro. The data, published in the online journal PLOS ONE, demonstrate how a therapeutic microRNA may help address drug resistance and increase the efficacy of single-gene targeted cancer therapy.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES